Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 3, 2004, Pages 783-786

  Khire, Uday R ^a   Bankston, Donald ^a   Barbosa, James ^a   Brittelli, David R ^a   Caringal, Yolanda ^a   Carlson, Robert ^a   Dumas, Jacques ^a   Gane, Todd ^a   Heald, Sarah L ^a   Hibner, Barbara ^a   Johnson, Jeffrey S ^a   Katz, Michael E ^a   Kennure, Nancy ^a   Kingery Wood, Jill ^a   Lee, Wendy ^a   Liu, Xiao Gao ^a   Lowinger, Timothy B ^a   McAlexander, Ian ^a   Monahan, Mary Katherine ^a   Natero, Reina ^a   Renick, Joel ^a   Riedl, Bernd ^a   Rong, Hong ^a   Sibley, Robert N ^a   Smith, Roger A ^a   Wolanin, Donald ^a   more..

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CARBOXYL GROUP; PHOSPHOTRANSFERASE INHIBITOR; RAF PROTEIN; SORAFENIB; UREA DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; DRUG SOLUBILITY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

EID: 1642534327     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.11.041     Document Type: Article

References (12)

1. Dumas J. Exp. Opin. Ther. Pat. 11:2001;. , 405, and references cited therein.
2. Chandra Kumar S., Madison V. Exp. Opin. Emerg. Drugs. 6:2001;303.
3. Bridges A. Curr. Med. Chem. 6:1999;825.
4. Lyons J.F., Wilhelm S.M., Hibner B., Bollag G. Endocr.-Relat. Cancer. 8:2001;219.
5. 50=0.54 μM (n=6).
6. Lowinger T.B., Riedl B., Dumas J., Smith R.A. Curr. Pharm. Des. 8:2002;99.
7. Riedl, B.; Lowinger, T. B.; Bankston, D.; Barbosa, J.; Brittelli, D. R.; Carlson, R.; Dumas, J.; Hibner, B.; Kadono, H.; Katz, M.: Kennure, N.; Khire, U.; Lee, W.; Monahan, M.-K.; Natero, R.; Renick, J.; Rong, H.; Scott, W. J.; Sibley, R. N.; Smith, R. A., Wood, J. 92nd Meeting of the American Association for Cancer Research, New Orleans, March 24-28, 2001; Abstract 4956.
8. Miller S., Osterhout M., Dumas J., Khire U., Lowinger T., Riedl B., Scott W., Smith R., Wood J., Rodriguez M., Wang M. PCT Int. Appl., WO 99/32436. Chem. Abstr. 131:1999;58658.
9. Riedl B., Dumas J., Khire U., Lowinger T.B., Scott W.J., Smith R.A., Wood J.E., Monahan M.-K., Natero R., Renick J., Sibley R.N. PCT Int. Appl., WO 00/42012. Chem. Abstr. 133:2000;120157.
10. 50 value.
11. For water solubilizing groups we specifically focused on substituents with heteroatoms that could add hydrophilicity or provide a site for salt formation. For a discussion on importance of the aqueous solubility as a drug-like property: Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Deliv. Rev. 2001, 46, 3, and references cited therein. Huuskonen, J. Combin. Chem., High Throughput Screen. 2001, 4, 311.
12. Heald, S. H.; Blake, P. C. Am. Pharm. Rev. In press.